Published : 24 Jul 2020

---

A Silicon Valley based company has appointed Aagami to support their investment needs.

 

The client is developing and commercializing a magnetic injection delivery system that will be able to  safely, effectively, and non-invasively deliver therapy to targets in the body that are currently not effectively reached by the standards-of-care, or that may otherwise require surgery to reach.

 

There are multiple large markets with unmet medical needs that this technology potentially addresses.

·      Ear

·      Eye

·      Skin

 

Funds raised so far from Investors

Raised over $10M in non-dilutive grants & NIH contracts. Closed $2.33M in Series A. 

Aagami to support in getting further investments for the current round of $5M bridge to Series B.  We at Aagami are very excited about this opportunity of a unique technology platform that will revolutionize the delivery of therapy to not currently reached places in human body. 

 

If you as an investor would like to know more, please contact us. We will happily share a deck for your evaluation. We also have all investment documents ready to share.

 

Contact information:

 

Godwyn Francis

Vice President

 

Aagami, Inc.                                               

2135 City Gate Lane, Suite 300

Naperville IL 60563

 

P:  +1-630-364-1837

E: godwyn@aagami.com